Crdentia Announces John Kaiser as New Chief Executive Officer, Also Joins Board of Directors
March 09 2007 - 6:00AM
PR Newswire (US)
DALLAS, March 9 /PRNewswire-FirstCall/ -- Crdentia Corp. (OTC:CRDT)
(BULLETIN BOARD: CRDT) , a leading U.S. provider of healthcare
staffing services, today announced the hiring of a new Chief
Executive Officer, John Kaiser, to fill the open position. Kaiser
joins Crdentia after an extensive career in the healthcare industry
including senior management positions at large corporations such as
Behringer Mannheim (Roche), Abbott Laboratories and The Upjohn
Company as well as smaller companies such as Biocircuits
Corporation and Aperon Biosystems. Kaiser also joins the Board of
Directors of Crdentia and assumes the CEO position effective March
26, 2007. Kaiser commented, "Crdentia presents a very attractive
and interesting opportunity. It is a company with solid
fundamentals that is positioned for growth. The Company has a
record of competing successfully in major markets against its
larger competitors. I fully expect that we will continue to do so,
and in the process grow revenues and profits from existing
operations while taking advantage of selected strategic
acquisitions that truly add value. I am excited about the
opportunity." Chairman, C. Fred Toney, stated, "On behalf of the
entire board of directors, we are pleased to fill the CEO position
with such a highly qualified and experienced healthcare management
professional. I have known John during his career in healthcare for
a long time and welcome his thoughtful but tenacious approach to
driving growth in revenues and profits for companies. John is an
operations expert who can focus heavily on the internal growth of
the Company while we continue to seek additional targeted strategic
healthcare staffing operations." Most recently, Kaiser was CEO,
Aperon Biosystems, where he raised $4 million of Series A venture
funding for this medical company; completed development of
prototype systems; raised a $14.3 million Series B venture funding
with a 60% step up in valuation; and moved the company to a new
facility to facilitate expansion of development and manufacturing.
Previously, Kaiser was Founder and CEO of VetMedSupply where he
raised $1.2 million for this start up. Previously, for eight years,
Kaiser was President, CEO and Chairman of Biocircuits where he was
recruited shortly after the Series A venture funding; raised the
Series B venture funding and then completed an initial public
offering in 1992; its product was launched in 1996 and a marketing
deal was completed with Becton Dickinson in 1997. Previously for
ten years, Kaiser held senior positions at Boehringer Mannheim
Corp. (currently Roche) including: President, Physician Laboratory
product Division; President, Patient Care Division; VP Sales and
Marketing, Patient Care Division; and VP Sales and Marketing,
Biodynamics Division. For ten years prior to that, Kaiser held
positions at Abbott including: Business Unit Manager, Abbott
Diagnostics; and Marketing Manager, Abbott Diagnostics. Previously,
he held positions at The Upjohn Company and Sales and Marketing
positions within the agricultural drug and chemical industry.
Kaiser received his BS degree from the University of Wisconsin.
About Crdentia Corp. Crdentia Corp. is one of the nation's leading
providers of healthcare staffing services to 1,500 healthcare
providers in 49 states. Crdentia provides high quality temporary
healthcare staffing comprised of travel and per diem nursing, locum
tenens, and allied healthcare staffing. For more information, visit
http://www.crdentia.com/. Forward Looking Statements Statements
contained in this release that are not historical facts are
forward-looking statements that involve risks and uncertainties.
Among the important factors which could cause actual results to
differ materially from those in the forward-looking statements
include, but are not limited to, those discussed in "Risk Factors"
in the Company's Forms 10-KSB, Forms 10-QSB, and other filings with
the Securities and Exchange Commission. Such risk factors include,
but are not limited to, a limited operating history with no
earnings; reliance on the Company's management team, members of
which have other business interests; the ability to successfully
implement the Company's business plan; the ability to continue as a
going concern; the ability to fund the Company's business and
acquisition strategy; the growth of the temporary healthcare
professional staffing business; difficulty in managing operations
of acquired businesses; uncertainty in government regulation of the
healthcare industry; and the limited public market for the
Company's common stock. The actual results that the Company
achieves may differ materially from any forward-looking statements
due to such risks and uncertainties. We undertake no obligation to
revise or update publicly any forward-looking statements for any
reason. For Further Information: AT THE COMPANY: AT FINANCIAL
RELATIONS BOARD: James J. TerBeest Lasse Glassen Chief Financial
Officer 310-854-8313 972-850-0780 DATASOURCE: Crdentia Corp.
CONTACT: James J. TerBeest, Chief Financial Officer of Crdentia
Corp., +1-972-850-0780, or Lasse Glassen of Financial Relations
Board, +1-310-854-8313, , for Crdentia Corp. Web site:
http://www.crdentia.com/
Copyright